Article
Biochemistry & Molecular Biology
Hisayuki Katsuyama, Mariko Hakoshima, Shohei Umeyama, Sakura Iida, Hiroki Adachi, Hidekatsu Yanai
Summary: This study aimed to examine the real-world efficacy of GLP-1RA dulaglutide on metabolic parameters in Japanese patients with T2DM. The 12-month dulaglutide treatment reduced body weight by 1.7 kg and hemoglobin A1c by 1.1%. Significant improvements were also observed in serum HDL-C, TG, and non-HDL-C.
Article
Medicine, General & Internal
Maria Mirabelli, Eusebio Chiefari, Vera Tocci, Patrizia Caroleo, Stefania Giuliano, Emanuela Greco, Raul Miguel Luque, Luigi Puccio, Daniela Patrizia Foti, Antonio Aversa, Antonio Brunetti
Summary: This study aimed to evaluate the 18-month safety and effectiveness of the GLP-1 receptor agonist dulaglutide as an add-on to metformin in overweight and obese patients with type 2 diabetes. The results showed that dulaglutide had durable and stable effects on HbA1c reduction and weight loss, with a significantly higher percentage of patients reaching glycemic targets compared to liraglutide at 18 months.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Joao Sergio Neves, Marta Borges-Canha, Francisco Vasques-Novoa, Jennifer B. Green, Lawrence A. Leiter, Christopher B. Granger, Davide Carvalho, Adelino Leite-Moreira, Adrian F. Hernandez, Stefano Del Prato, John J. V. McMurray, Joao Pedro Ferreira Md
Summary: This study aimed to evaluate the effects of GLP-1 receptor agonists (GLP-1 RAs) on cardiovascular outcomes in patients with type 2 diabetes (T2D) treated with or without SGLT2 inhibitors. The results showed that GLP-1 RAs reduced cardiovascular events independently of SGLT2 inhibitor use, suggesting that the combination of GLP-1 RAs with SGLT2 inhibitors may further reduce cardiovascular risk.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Endocrinology & Metabolism
Youngsook Kim, Ji Hye Huh, Minyoung Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
Summary: This study aimed to investigate whether switching to dulaglutide improves glycemic control in patients with type 2 diabetes inadequately controlled with conventional insulin treatment. Retrospective evaluation of real-world data found that a considerable proportion of patients successfully switched from insulin to the GLP-1 receptor agonist. Younger age, lower insulin dose, and higher baseline postprandial glucose level may predict successful switching.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Hwi Seung Kim, Chang Hee Jung
Summary: GLP-1 is a hormone secreted by the gastrointestinal tract that can stimulate insulin secretion, reduce hunger, and promote weight loss. Oral semaglutide, the first ingestible GLP-1RA, has shown efficacy in glycemic management, weight loss, and cardiovascular safety, making it a novel treatment option for patients with type 2 diabetes and/or obesity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Endocrinology & Metabolism
Angela Dardano, Michele Aragona, Giuseppe Daniele, Roberto Miccoli, Stefano Del Prato
Summary: This study suggests that GLP-1 receptor agonist therapy may be effective and safe for the treatment of type 2 diabetes with high cardiovascular risk in people living with HIV.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Hwi Seung Kim, Yun Kyung Cho, Myung Jin Kim, Chang Hee Jung, Joong-Yeol Park, Woo Je Lee
Summary: This retrospective study evaluated the long-term efficacy of dulaglutide in participants with type 2 diabetes mellitus. The results showed that long-term dulaglutide treatment was effective in maintaining glycemic control and reducing weight, suggesting that dulaglutide could be a favorable option for long-term treatment in real-world clinical practice.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Endocrinology & Metabolism
Thomas Karagiannis, Ioannis Avgerinos, Aris Liakos, Stefano Del Prato, David R. Matthews, Apostolos Tsapas, Eleni Bekiari
Summary: This study conducted a systematic review and meta-analysis to evaluate the efficacy and safety of tirzepatide for type 2 diabetes. The results showed that tirzepatide had dose-dependent superiority in lowering HbA(1c) and reducing body weight compared to placebo, GLP-1 RAs, and basal insulin. However, tirzepatide was associated with an increased incidence of gastrointestinal adverse events.
Article
Endocrinology & Metabolism
Jiwoo Lee, Hwi Seung Kim, Chang Hee Jung, Joong-Yeol Park, Woo Je Lee
Summary: Switching from insulin to dulaglutide can significantly improve HbA1c levels and reduce body weight in patients with type 2 diabetes over 6 months. Patients with higher baseline HbA1c levels tend to have a better clinical response to dulaglutide treatment.
DIABETES-METABOLISM RESEARCH AND REVIEWS
(2021)
Review
Cardiac & Cardiovascular Systems
Michael A. Nauck, David A. D'Alessio
Summary: Tirzepatide, the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes, has shown to be effective in reducing HbA(1c) and body weight, and has good cardiovascular safety. However, there are still questions regarding its mechanism of action.
CARDIOVASCULAR DIABETOLOGY
(2022)
Review
Endocrinology & Metabolism
Christophe E. M. De Block, Eveline Dirinck, Ann Verhaegen, Luc F. Van Gaal
Summary: Glucagon-like peptide-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic peptide RA tirzepatide have expanded the population of individuals reaching HbA1c and weight targets, showing potential therapeutic benefits. However, further research is needed to determine whether this will lead to improved cardiovascular outcomes and impact treatment guidelines.
DIABETES OBESITY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Aditi R. Saxena, Juan P. Frias, Donal N. Gorman, Rene N. Lopez, Nabil Andrawis, Nikolaos Tsamandouras, Morris J. Birnbaum
Summary: This study aimed to evaluate the tolerability, safety, and pharmacodynamics of different dose escalation schemes of danuglipron, an oral small-molecule GLP1R agonist. The results showed that danuglipron significantly reduced glycated hemoglobin, fasting plasma glucose, and body weight over 12 weeks, but had higher discontinuation rates and incidence of gastrointestinal adverse events.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Junpei Sanada, Tomohiko Kimura, Masashi Shimoda, Akiko Tomita, Yoshiro Fushimi, Tomoe Kinoshita, Atsushi Obata, Seizo Okauchi, Hidenori Hirukawa, Kenji Kohara, Fuminori Tatsumi, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
Summary: The study demonstrates that switching from daily DPP-4 inhibitors to dulaglutide has a significantly positive impact on glycemic control in subjects with type 2 diabetes mellitus, especially in those with poor glycemic control.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Knud Josefsen, Lars Krogvold, Ivan C. Gerling, Flemming Pociot, Knut Dahl-Jorgensen, Karsten Buschard
Summary: This study suggests that dormant beta cells in type 1 diabetes (T1D) exhibit secretion defects, fetal dedifferentiation, and desynchronization. Combining with previous evidence, it is proposed to treat individuals with ongoing T1D development prophylactically with type 2 diabetes (T2D) medicine and anti-inflammatory compounds to reactivate dormant beta cells and prevent autoimmune destruction. Further investigation into T2D mechanisms during T1D development is needed.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Melissa K. Thomas, Amir Nikooienejad, Ross Bray, Xuewei Cui, Jonathan Wilson, Kevin Duffin, Zvonko Milicevic, Axel Haupt, Deborah A. Robins
Summary: Tirzepatide demonstrated significantly greater improvements in insulin sensitivity and beta-cell function compared to dulaglutide, with only partial contributions from weight loss. The dual receptor agonism of tirzepatide may confer distinct mechanisms of glycemic control beyond just weight reduction.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)